Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by the subject or parent/guardian as appropriate; child assent as appropriate;~* Before the age of 19, met at least 4 of the 11 modified American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus as updated in 1997;~* Date of SLE diagnosis (as described in Inclusion Criterion 2) at least 24 weeks prior to randomization;~* Serum 25-hydroxyvitamin D \[25(OH)D\] \< 20 ng/mL at Screening;~* SELENA SLEDAI score \> 0 and \< 8 at Screening and at Baseline;~* If taking prednisone (or equivalent corticosteroid), the dose must be ≤ 15 mg/day or ≤0.5 mg/kg/day, whichever is lower, and stable for at least four weeks prior to randomization. Note, if subjects are taking steroids every other day, divide their dose by 2 to evaluate eligibility;~* Stable immunosuppressive dose for at least 12 weeks prior to randomization;~  --Immunosuppressive medications allowed include mycophenolate (MMF), azathioprine, methotrexate, antimalarial medications (e.g., hydroxychloroquine), cyclosporine A (CsA), tacrolimus, intravenous immune globulin (IVIG), and abatacept.~* Body weight \> 25 kg;~* Able to swallow pills;~* Males and females with reproductive potential must agree to practice effective measures of birth control.~Exclusion Criteria:~* Any condition or treatment that, in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the trial;~* Current pharmacologic vitamin D2 or D3 intake \> 800 IU daily or use of calcitriol at any dose over the past four weeks prior to randomization;~* Cyclophosphamide or IV glucocorticoid exposure within 12 weeks prior to randomization;~* Any BILAG A or B manifestation with the exception of a BILAG B mucocutaneous manifestation at screening, and excluding the renal BILAG criteria (see rituximab or belimumab criterion, below);~* Significant renal insufficiency defined as:~  * Estimated GFR \< 60 mL/min/1.73m\^2 or estimated GFR \< 90 mL/min/1.73m\^2 with a reduction of the GFR by \> 15% from the last measurement;~ * Urine dipstick value of 2+ or higher for protein, unless this is a stable value from the last measurement or, urine protein-creatinine ratio ≥ 50 mg/mmol unless the value represents an improvement of ≥ 25% from the last measurement.~* Rituximab or belimumab exposure use within 24 weeks prior to randomization;~* The following laboratory parameters at the Screening visit:~  * Platelets \< 50,000; WBC \< 2,500; ANC \< 1,000;~ * Hemoglobin \< 9 mg/dL;~ * ALT, AST, bilirubin \> 2x upper limit of normal (ULN);~ * Hypercalcemia (calcium \> ULN);~ * Hypercalciuria (urinary calcium/creatinine ratio \> 0.2).~* Primary hyperparathyroidism (known);~* History of nephrolithiasis (known);~* Diabetes mellitus requiring insulin therapy;~* Medications that interfere with vitamin D absorption;~* History of vertebral compression fractures (known);~* Pregnancy (girls ≥ 11 years of age must have a negative urine/serum pregnancy test);~* A history of non-adherence/non-compliance;~* Other investigational drug and/or treatment during the four weeks or seven half-lives of the other investigational drug prior to the start of study product dosing (Day 0), whichever is the greater length of time to enrollment;~* Current diagnosis of cancer or chronic infection such as Hepatitis B, Hepatitis C, or tuberculosis;~* Treatment with digoxin;~* Flu (influenza) vaccination within one week prior to randomization.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 6000 IU (Type: EXPERIMENTAL): 6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
- Vitamin D3 400 IU (Type: ACTIVE_COMPARATOR): 400 IU/day of vitamin D3 by mouth daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).